Last Updated : July 26, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | |||
Onivyde | Nanoliposomal Irinotecan | Cancelled | ||||
Venclexta | Venetoclax | Withdrawn | ||||
Cyramza | Ramucirumab | Cancelled | ||||
Praxbind | Idarucizumab (Drug Plan Submission) | Reversal of dabigatran anticoagulant effects | Withdrawn | |||
Avastin | Bevacizumab | Withdrawn | ||||
Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Oncaspar | pegaspargase | Adult Acute Lymphocytic Leukemia (ALL) | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Revolade | eltrombopag | Severe aplastic anemia | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
Viibryd | vilazodone | Depression, Major depressive disorder | Canada’s Drug Agency is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
TBD | Cabozantinib | Withdrawn | ||||
Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
Erbitux | Cetuximab | Cancelled | ||||
Lapelga | Pegfilgrastim | Febrile neutropenia | N/A | Complete | ||
Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | |||
Atriance | Nelarabine | Cancelled | ||||
TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
Zytiga (Resubmission) | Abiraterone | Prostate Cancer Resubmission | Withdrawn | |||
TBD | Entrectinib | Withdrawn | ||||
Tecentriq | Atezolizumab | Withdrawn | ||||
TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
Kineret | anakinra | Still's disease | Withdrawn | |||
Tysabri | natalizumab | Multiple Sclerosis, relapsing-remitting | Withdrawn | |||
Admelog | Insulin lispro | Cancelled |